Current Report Filing (8-k)
May 22 2023 - 4:17PM
Edgar (US Regulatory)
0000887247
false
--12-31
0000887247
2023-05-22
2023-05-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 22, 2023
ADAMIS PHARMACEUTICALS CORPORATION
(Exact
Name of Registrant as Specified in Charter)
Delaware |
|
0-26372 |
|
82-0429727 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
11682 El Camino Real, Suite 300
San Diego, CA |
|
92130 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (858) 997-2400
(Former name or Former Address, if Changed Since Last Report.)
___________________________________________
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock |
|
ADMP |
|
NASDAQ Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
Emerging growth company ☐ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
3.03. Material Modifications of Rights of Security Holders.
To
the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this report is incorporated herein by reference.
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
Adamis Pharmaceuticals
Corporation (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s
Restated Certificate of Incorporation (the “Restated Certificate”) with the Secretary of State of Delaware, effective 12:01
a.m. Eastern time, to effect a 1-for-70 reverse stock split of the outstanding shares of the Company’s common stock, par value $0.0001
per share (the “Common Stock”) (the “Reverse Stock Split”). As previously reported in a Form 8-K filed by the
Company on May 16, 2023, the Company held a special meeting of stockholders on May 15, 2023 (the “Special Meeting”), at which
meeting the Company’s stockholders approved the amendment to the Company’s Restated Certificate to effect a reverse stock
split of the Company’s common stock at a ratio in the range of 1-for-2 to 1-for-100, with such ratio to be determined by the Company’s
Board of Directors (the “Board”). Following the Special Meeting, the Board determined to effect the Reverse Stock Split at
a ratio of 1-for-70 and approved the corresponding final form of the Certificate of Amendment.
As
a result of the Reverse Stock Split, every 70 shares of issued and outstanding Common Stock will be automatically combined into one issued
and outstanding share of Common Stock, without any change in the par value per share. The Company will not issue any fractional shares
in the Reverse Stock Split. In lieu of such fractional shares, any stockholder who would otherwise be entitled to a fractional share
of Common Stock as a result of the Reverse Stock Split following the effective time of the Reverse Stock Split (after taking into account
all fractional shares of Common Stock otherwise issuable to such stockholder), will be entitled to receive a cash payment (without interest)
equal to the fair market value of the fraction to which such holder would otherwise be entitled multiplied by the fair market value of
the Common Stock as determined by the Board of Directors. The number of authorized shares of Common Stock under the Certificate of Incorporation
will remain unchanged at 200,000,000 shares.
Proportionate
adjustments will be made to the per share exercise price and the number of shares of Common Stock that may be acquired upon exercise
of outstanding stock options granted by the Company or outstanding warrants to purchase Common Stock previously issued by the Company,
or upon vesting of outstanding restricted stock units. The number of shares reserved for issuance under the Company’s 2020 Equity
Incentive Plan will be proportionately reduced in accordance with the terms of such plan.
The Common Stock will
begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market on May 22, 2023. The trading symbol for the Common
Stock will remain “ADMP.” The new CUSIP number for the Common Stock following the Reverse Stock Split is 00547W 307.
On May 19, 2023, the
Company issued a press release announcing the reverse stock split. A copy of the press release is filed as Exhibit 99.1 hereto.
For
more information about the Reverse Stock Split, see the Company’s definitive proxy statement filed with the U.S. Securities and
Exchange Commission on April 13, 2023 (the “Proxy Statement”), the relevant portions of which are incorporated herein by
reference. The information set forth herein is qualified in its entirety by reference to the complete text of the Certificate of Amendment,
a copy of which is filed with this report as Exhibit 3.1.
Item
9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
Exhibit No. |
|
Description |
3.1 |
|
Certificate of Amendment to the Restated Certificate of Incorporation of Adamis Pharmaceuticals Corporation. |
99.1 |
|
Press release dated May 19, 2023. |
104 |
|
Cover Page Interactive Data File (embedded within the
Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
ADAMIS PHARMACEUTICALS CORPORATION |
|
|
|
|
|
|
Dated: May 22, 2023 |
By: |
/s/ David C.
Benedicto |
|
Name: |
David C. Benedicto |
|
Title: |
Chief Financial Officer |
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Apr 2024 to May 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From May 2023 to May 2024